Summary We have measured the amount of fibroblast growth factor mRNA 
The fibroblast growth factors (FGFs) form a family of nine identified growth regulatory proteins that share 35-50% overall homology and induce proliferation and differentiation of a wide range of cells of epithelial, mesodermal and neuroectodermal origin (Gospodarowicz et al., 1987; Burgess and Maciag, 1989;  Klagsbrun, 1990; Goldfarb, 1990) . All, except FGF-1 and 2, are synthesised with an N-terminal hydrophobic signal sequence, enabling the classical mechanism of secretion from cells (Abraham et al., 1986; Jaye et al., 1986) . Release of FGF-1 and 2 may occur through leakage from damaged cells or from viable cells through a novel mechanism (Mignatti et al., 1992; Cao and Pettersson, 1993) . FGF-1 and 2 have both been reported to show nuclear as well as cytoplasmic localisation (Cao and Pettersson, 1993; Vijayan et al., 1993) .
The response of cells to FGFs is mediated through formation of a ternary complex of growth factor, proteoglycan and high-affinity receptor (Yayon et al., 1991; Klagsbrun and Baird 1991; Rapraeger et al., 1991; Ornitz et al., 1992; Kan et al., 1993) . A family of tyrosine kinase receptors encoded by at least four separate genes [FGF receptor (R)-l-4] have recently been identified (Lee et al., 1989; Dionne et al., 1990; Kornbluth et al., 1988; Keegan et al., 1991; Partanen et al., 1991; Mansukhani et al., 1992) . The complexity of this family is enhanced by an array of spliced variants resulting in receptors with altered ligand binding and signalling characteristics (Hou et al., 1991; Johnson et al., 1991; Jaye et al., 1992; Miki et al., 1992; Yayon et al., 1992) .
We have previously shown that FGF-1 and 2 are both present in human breast tissue (Gomm et al., 1991; Luqmani et al., 1992; Smith et al., 1994) . FGF-2 has been localised to the myoepithelial cells of normal breast by immunocytochemistry but could not be detected in either normal or malignant epithelial cells (Gomm et al., 1991) . Bioassayable FGF-1 was present in conditioned medium from breast cancer biopsies (Smith et al., 1994 (Barritauld et al., 1991) . More recently, studies have been carried out that implicate autocrine and intracrine mechanisms in some carcinoma cells since FGF-1 and its receptor are co-expressed and FGF-1 stimulated proliferation (Chao et al., 1993 FGF-1 in human breast GS Bansal et al 1421 adjacent to carcinoma or from benign conditions histologically confirmed to be non-malignant was also collected and is referred to as normal. Breast organoids were prepared from normal breast tissues obtained from reduction mammoplasties, essentially by the method described by Stampfer et al. (1980) .
Immunohistochemistry
Immunocytochemistry was carried out using a mouse monoclonal antibody raised in collaboration with J Walters (Brookes University, Oxford, UK) against a 38 amino acid peptide sequence of FGF-1 corresponding to amino acids 60-98. The full characterisation of this antibody is the subject of another report (R Coope et al., in preparation). Briefly, cryostat sections (7-10gM) of breast tissue were incubated with the FGF-1 antibody overnight at 4°C. Sections were then incubated with biotinylated anti-mouse IgG followed by an avidin-biotin peroxidase complex. Staining was visualised using 0.05% 3-diaminobenzidine and counterstained with Gill's haematoxylin.
SDS-PAGE and Western blotting
Monolayers of cultured cells grown in petri dishes were lysed in standard SDS-PAGE sample buffer. Frozen tissue samples were pulverised to a fine powder and also dissolved in lysis buffer. All samples were sonicated for 30 s using a sonicator at maximum output. Aliquots of 50 yg of protein (Bradford, 1976) were electrophoresed through a 15% polyacrylamide gel and the separated proteins were transferred onto nitrocellulose membranes by overnight blotting at 4°C. After blocking with 3% milk powder in phosphate-buffered saline (PBS) supplemented with 0.1% Tween 20 (PBS-T) for 1 h at 20°C, the membranes were incubated with a commercially available rabbit polyclonal anti-FGF-I antibody (British Biotechnology) for 1 h. The blots were then incubated, after washing, for 1 h with an anti-rabbit IgG conjugated to horseradish peroxidase. After five washes with PBS-T, bands were visualised using the ECL method (Amersham, UK), as described in the manufacturer's protocol.
Determination of FGF-I mRNA by RT-PCR amplication Cellular RNA was extracted from pulverised frozen tissues using the guanidinum isothiocyanate method (Chirgwin et al., 1979) and from the cell lines by the modified RNAzol procedure (Chomczynski and Saachi, 1987) . Reverse transcription and PCR amplification was performed as described previously (Luqmani et al., 1992) . Briefly, 2 Lg of RNA was reverse transcribed using random primers and cDNA was amplified using 1 unit of Taq polymerase in 100 pl containing 200 ng of each of the FGF-l and actin primers, by sequential cycles of denaturation at 94°C for 1 min, annealing at 45°C for 1 min and extension at 72°C for 1 min (extended to 10 min for the final cycle). An aliquot was removed after 18 cycles for estimation of actin product and the reaction continued for a further ten cycles for estimation of FGF-1.
Aliquots (10 pl) of the 28-cycle and 18-cycle PCR products were electrophoresed on separate 1% agarose gels and alkali blotted overnight onto Hybond N+ membrane (Luqmani et al., 1992) .
Hybridisation was carried out as described by Church and Gilbert (1984) . We initially used plasmids containing FGF-1 or actin cDNA for hybridisations to verify identity and size of PCR products. As single bands were seen, we subsequently used PCR products (made using plasmid template) random primer labelled (Feinberg and Vogelstein 1983) fig-' ; 106 c.p.m. ml-'). Washed blots were exposed to hyperfilm for several hours and band intensities were quantified by densitometry.
The value for FGF-1 was normalised by dividing the signal for FGF-1 by that for actin. Separate blots were normalised to each other by using an arbitrary sample, which was present on every run and every blot, to correct for differences FGF- 
Results
Expression of FGF-I mRNA in breast tissues PCR conditions were optimised as described before (Luqmani et al., 1992) to ensure that amplification was within the linear phase. Eighteen cycles of PCR were selected for estimation of actin levels and 28 cycles for FGF-1 (data not shown). All 37 normal and 116 neoplastic breast tissues examined produced the expected FGF-1 PCR product of 135 bp. In each case a single band corresponding to 319 bp was also seen for actin. However, the levels of amplified FGF-1 were significantly higher (P = 0.00 1) in the normal tissues: the median value for FGF-1/actin ratio in normal tissues was 23.3 (range 2.4-489) compared with 5.7 (range 0.29-157) in breast cancer tissues (Figure 1 ).
Correlation of FGF-J mRNA expression in cancers with clinical parameters The details of the patients studied are summarised in Table I. Our results were analysed with respect to five prognostic parameters: T stage, pathological size, nodal involvement, oestrogen receptor status and menstrual status (see Table II) . No relationship was seen between FGF-l mRNA levels and any of these prognostic parameters. Although clinical T staging appeared to correlate with FGF-l mRNA levels (P < 0.05), this was not confirmed when we examined the relationship with pathological tumour size. There was no relationship between FGF-1 mRNA content and time to relapse or overall survival in the patients studied (P = 0.817 and 0.297 respectively).
observed three bands corresponding to 14, 16 and 18 kDa peptides (Figure 2 blot experiments (R Coope et al., manuscript in preparation). In cryostat sections, FGF-1 immunostaining was only detected in normal breast epithelial cells. Figure 3a demonstrates FGF-1 staining of the epithelium of a normal duct adjacent to non-staining malignant epithelial cells on a breast cancer section. Figure 3b is the negative control of the same tissue treated with non-immune mouse IgG. At a higher magnification, Figure 3c shows intense FGF-1 staining associated with the cytoplasm and membrane of normal epithelial cells. No nuclear localisation was seen. We believe the epithelial cell staining to be specific since the peptide to which the antibody was raised was able to block the staining (R Coope et al., manuscript in preparation).
Expression of FGF-I mRNA and protein in breast cell lines We examined mRNA from 14 breast cell lines. FGF-1 product was obtained from all of these lines but levels were generally higher in the three non-malignant cell lines. (HBRSVI.6.1, HBL100 and MCF1Oa) as compared with the majority of the cancer derived lines; two of the cancer cell lines (MDA-MB-361 and SKBR111), however, also had levels similar to the non-malignant lines (Figure 4a ). We also found FGF-1 product in all of the ten non-mammary cell lines examined, with the A204 cells having the highest levels (similar to those found in the breast tissues) (Figure 4b Figure 5 ). Immunostaining of these cell lines gave similar results (data not shown) with staining seen only in the non-malignant lines. In summary, the non-malignant cell lines of both myoepithelial and epithelial origin contain both the FGF-1 mRNA and the translated protein whereas the changes involved in carcinogenesis have led to a reduction in the expression of FGF-1 in 80% of the malignant cell lines tested.
Discussion
In this study, we have compared the expression of FGF-1 mRNA and protein in malignant and non-malignant breast using 153 tissue samples and 14 breast derived cell lines. Using all methods we noted a decrease in the expression of FGF-I in breast cancer. Semiquantitative PCR allowed the detection of FGF-I mRNA in all the tissue samples, however the levels seen in cancers were significantly lower than those seen in non-malignant tissues. This finding is in marked contrast to a study of FGF-1 expression in pancreatic cancer in which FGF-1 mRNA was found to be overexpressed in cancer with expression levels correlating with tumour stage (Yamanaka et al., 1993) .
We have confirmed our results by using Western blotting to monitor the level of FGF-l protein present in breast tissues. The same pattern of expression is seen, with nonmalignant cell lines and tissue samples containing higher levels of FGF-1 than cancer cell lines and tissue samples. FGF-I would be expected to be translated as a single form of 18 kDa and this single band is seen in all benign cell lines and tissues analysed (Burgess and Maciag, 1989; Cao and Pettersson, 1993) . Additional bands of 14 kDa and 16 kDa are seen in reduction mammoplasty tissue. This process was required because the higher fat content of non-malignant tissue compared with breast tumours made it difficult to achieve lysates of normal tissue with protein concentrations similar to those of the cancer sample lysates without using organoid preparation as a way of enriching for cells.
The cellular localisation of FGF-I was studied on cryostat sections using immunohistochemistry. FGF-I protein was found predominantly in the luminal epithelial cells of normal ducts. This is in agreement with a previous study showing strong anti-FGF-l immunoreactivity in the glandular epithelium (Hughes and Hall, 1993) . Again, a large decrease in FGF-1 expression was seen in breast cancer, with no staining apparent in breast cancer cells. Thus luminal epithelial cells normally express FGF-1 and transformation of these cells results in loss of expression of FGF-1.
The study of FGF-1 expression in breast-derived cell lines showed that non-malignant cell lines of both epithelial and myoepithelial phenotypes expressed FGF-1. We observe staining only on the luminal epithelial cells of cryostat sections and two theories could explain this difference. One possibility is that myoepithelial cells do not express FGF-l under normal (Luqmani et al., 1992; Jacquemier et al., 1994; McLeskey et al., 1994) . This raises the possibility that FGF-1 has roles in autocrine or paracrine control of epithelial and myoepithelial cells in the normal duct. The role of FGF-1 in the normal duct is unclear since, although (Jaakkola et al., 1993) .
Increased expression of FGFR-1 has been found in 15% of breast tumours and a panel of breast cancer cell lines show amplification of either FGFR-1 or FGFR-4 in several cell lines (Jacquemier et al., 1994; McLeskey et al., 1994) . Both of these receptors would bind FGF-1 with high affinity, however in the absence of FGF-1 in breast cancer it is possible that these overexpressed receptors will be activated by an alternative ligand such as FGF-4 or FGF-6, although neither of these has been detected in the breast (Vainikka et al., 1992) . It has recently been reported that FGF receptors also interact with adhesion molecules, with such interactions leading to receptor activation and Ca2" influx (Williams et al., 1994) . It is possible that alternative interactions such as these are responsible for stimulating the overexpressed FGF receptors in breast cancer.
The decrease in FGF-1 expression in breast cancer cells is striking. It is a frequent change occurring in carcinogenesis since at least 80% of breast cancers contain no detectable FGF-I by Western blot analysis and immunohistochemistry. Further investigation will be required to assess the functional effect of the decrease in this growth factor. The presence of FGF-l and its receptors in the normal breast suggests a role for this factor in the maintenance of the normal duct. The decrease in FGF-1 in cancer would be expected to perturb Abbreviations FGF-1 and -2, acidic and basic fibroblast growth factor; FGFR, fibroblast growth factor receptor; RT, reverse transcriptase; PCR, polymerase chain reaction.
